wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38404422-D5FB0202-2E40-42F9-97F0-0225B4FB236A
Q38404422-D5FB0202-2E40-42F9-97F0-0225B4FB236A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-D5FB0202-2E40-42F9-97F0-0225B4FB236A
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
P2860
Q38404422-D5FB0202-2E40-42F9-97F0-0225B4FB236A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-D5FB0202-2E40-42F9-97F0-0225B4FB236A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
38c4135fe57d9f81540a31d707b3606ba694db31
P2860
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.